Monitor upcoming APOLLO study data in Q2 2026 and the initiation of the company-sponsored pancreatic cancer program, which could serve as key catalysts. The reduced R&D spend despite advancing multiple programs suggests improved efficiency, but the increasing net loss warrants attention to future funding needs.
MRKR drugs
MRKR drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 19 $1.32entry
- T+1 · 8mo ago +1.52%α +3.26% · $1.34
- T+5 · 8mo ago +2.27%α +4.48% · $1.35
- T+20 · 7mo ago +25.76%α +18.14% · $1.66
- T+60 · 5mo ago +4.55%α −9.80% · $1.38
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Marker Therapeutics reported its 2025 financial results and provided clinical updates, highlighting a 66% objective response rate in relapsed non-Hodgkin lymphoma from its APOLLO study and promising pancreatic cancer research published in Nature Medicine. The company ended 2025 with $17 million in cash, sufficient to fund operations through Q4 2026, while R&D expenses decreased to $11.8 million. The stock has a market cap of $22 million.
Key Financial Metrics
Key Facts
- 66% objective response rate (8/12 patients) in relapsed non-Hodgkin lymphoma with MT-601 therapy, including 50% complete responses
- 78% objective response rate (7/9 patients) in Hodgkin lymphoma
- Nature Medicine publication showed up to 84.6% disease control rate in pancreatic cancer when combined with chemotherapy
- Cash position of $17 million at year-end 2025, expected to fund operations through Q4 2026
- R&D expenses decreased to $11.8 million in 2025 from $13.5 million in 2024
- Net loss increased to $12.2 million in 2025 from $10.7 million in 2024
Financial Impact
Net loss increased by $1.5 million year-over-year while R&D spending decreased by $1.7 million, with cash burn of $12.0 million from operations
Risk Factors
- Clinical trial results are from small patient cohorts (8-12 patients) and may not be reproducible in larger studies
- Company has limited cash runway with funding expected only through Q4 2026, raising potential dilution risk
- Increased net loss despite lower R&D expenses indicates ongoing financial pressure
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-031309 |
| Document: tm268941d1_8k.htm | 0001104659-26-031309 |
| Document: 0001104659-26-031309-index-headers.html | 0001104659-26-031309 |
| Document: 0001104659-26-031309-index.html | 0001104659-26-031309 |
| Document: 0001104659-26-031309.txt | 0001104659-26-031309 |
Track record
5 reports on MRKR
The track record builds as more bullish or bearish reports settle.
Filters
- Oct 19, 202628d ago 8-K Bullish 5/10 Entry $1.20 to $0.8700 Now $0.8300 −30.83% ▼ −27.50% −24.04% vs SPY
- Oct 19, 202628d ago Press Release Bullish 5/10 Entry $1.20 to $0.8286 Now $0.8300 −30.83% ▼ −30.95% −27.49% vs SPY
- Mar 20, 202634w ago DEFA14A Neutral 4/10 Entry $1.31 to $1.56 Now $0.8300 −36.64% ▲ +19.08% +11.66% vs SPY
- Mar 19, 202634w ago 8-K Mixed 6/10 Viewing Entry $1.32 to $1.66 Now $0.8300 −37.12% ▲ +25.76% +18.14% vs SPY
- Mar 18, 202634w ago Press Release Mixed 6/10 Entry $1.32 to $1.66 Now $0.8300 −37.12% ▲ +25.76% +18.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers